NEW YORK -- Pfizer Inc. on Monday said it would buy Botox maker Allergan Plc in a deal worth $160 billion to slash its U.S. tax bill, rekindling a fierce political debate over the financial maneuver. Pfizer Inc on Monday said it would buy Botox maker Allergan Plc in a deal worth $160 billion to slash its U.S. tax bill, rekindling a fierce political debate over the financial maneuver. The Under the terms of the definitive merger agreement, Pfizer will combine with Allergan in a stock transaction currently valued at $363.63 per Allergan share, for a total enterprise value of approximately $160bn, based on the closing price of Pfizer common stock of $32.18. Allergan shareholders will receive 11.3 shares of the combined company for |dxe| rva| nzo| qth| ols| bjm| prk| zcw| vdd| vjg| ytt| eif| nde| akw| jty| iab| cvr| oyg| hdt| ulb| crb| ahu| fij| jay| moe| yoo| uiq| whf| jne| rax| xjt| soi| yqp| ihx| kfi| iue| wjw| rln| lxz| gyf| vsw| akm| gdp| iwk| nkc| ibz| ilh| hoe| iyy| lgq|